Introduction
============

Optic neuritis is an acute multi-aetiological inflammatory condition affecting the optic nerve causing retro-orbital pain and visual loss. Optic neuritis is highly associated with multiple sclerosis, and 50% of cases develop multiple sclerosis after 15 years ([@awv203-B23]). MRI currently provides one of the best risk stratification markers for later conversion to multiple sclerosis, as 72% of cases having more than one multiple sclerosis-specific white matter lesion at baseline subsequently develop multiple sclerosis, as opposed to 25% with no multiple sclerosis-specific lesions at baseline ([@awv203-B23]). We have recently published data showing that patients with multiple sclerosis have a higher permeability of the blood--brain barrier (BBB) in the normal-appearing white matter when compared to healthy control subjects, and furthermore, when patients had recently experienced a clinical relapse the permeability increased significantly.

The optic nerve is considered a part of the CNS as it is derived from an out-pouching of the diencephalon during embryonic development. As a consequence of this it shares many histological characteristics with the diencephalon, i.e. myelination is produced by oligodendrocytes, it is ensheathed by three meningeal layers and has a BBB, etc. During acute optic neuritis, a common MRI finding is contrast enhancement of the optic nerve, indicative of BBB breakdown. However, little is known of the behaviour of the BBB in the normal-appearing tissue of the telencephalon during the acute stages of optic neuritis. Therefore, we wanted to investigate whether patients with optic neuritis also have changes of the BBB permeability in normal-appearing white matter normal as we have seen in patients with multiple sclerosis ([@awv203-B7]). In addition, we wanted to investigate if a leakier BBB in these patients could be related to other measures of neuroinflammation, and whether the degree of leakiness could be related to the likelihood of developing multiple sclerosis within a period of 2 years. The BBB permeability was investigated by use of dynamic contrast-enhanced T~1~-weighted MRI (DCE-MRI) ([@awv203-B17]).

Materials and methods
=====================

Optic neuritis patients and healthy volunteers
----------------------------------------------

Thirty-nine patients with acute optic neuritis were enrolled prospectively in the study. From June 2011 to December 2012 134 patients were referred by ophthalmologists to the Clinic of Optic Neuritis, Glostrup Hospital with suspected optic neuritis. Diagnostic criteria were as previously described ([@awv203-B21]). In short, inclusion criteria were: a diagnosis of optic neuritis, time from onset of visual symptoms to MRI and lumbar puncture ≤28 days, age between 18 and 59 years and no prior symptoms of demyelinating disease. Thirty-nine (60%) of 65 eligible patients participated in the study ([Supplementary Fig. 1](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awv203/-/DC1)).

Multiple sclerosis diagnosis and risk factors
---------------------------------------------

A diagnosis of multiple sclerosis was made by experienced multiple sclerosis clinicians using the revised 2010 McDonald criteria ([@awv203-B24]). As MRI risk factors of multiple sclerosis we chose T~2~ lesion count, divided into three categories (0--1 lesion, 2--8 lesions and \>9 lesions) based on previous results showing low and high risk of multiple sclerosis in the 0--1 lesion group and \>9 lesions groups, respectively ([@awv203-B2]; [@awv203-B29]; [@awv203-B23]). Information on multiple sclerosis development was acquired from hospital records 2 years after optic neuritis onset.

Healthy controls
----------------

Eighteen healthy controls were enrolled on the basis of age and gender, 12 of these were part of a previously described group ([@awv203-B21]) who underwent lumbar puncture. None had a history of autoimmune, neurological, or chronic illness, nor any prior symptoms or family history of demyelinating disease. All underwent a thorough clinical and neurological examination. Multiple sclerosis patients and healthy controls had MRI scans performed in an interleaved fashion to minimize the impact of slight scanner hardware differences (i.e. scanner drift) over time on the results.

CSF sampling and biomarker analysis
-----------------------------------

All 39 patients gave consent for usage of routine lumbar puncture values \[CSF leucocyte count, immunoglobulin G (IgG) index and oligoclonal bands\], whereas 34 of 39 patients gave consent for acquisition of additional study biomarkers from CSF. Twelve of 18 healthy controls gave consent for lumbar puncture and acquisition of study biomarkers. Routine analysis included CSF leucocyte and erythrocyte counts, measurement of CSF protein and glucose levels, IgG index and albumin quotient and test for oligoclonal bands by isoelectric focusing and immunoblotting. CSF (12 ml) was collected in an ice bath and immediately centrifuged at 400*g* at 4°C for 10 min, and the cell-free supernatant was frozen and stored in 0.5 ml aliquots at −80°C until analysis. Levels of the biomarkers C-X-C motif chemokine 10 (CLCX10), C-X-C motif chemokine 13 (CLCX13) and matrix metalloproteinase 9 (MMP9) were analysed by enzyme-linked immunosorbent assays (ELISA) using commercially available kits as previously described ([@awv203-B21]).

Imaging
-------

### Magnetic resonance sequences and regions of interest

MRI was performed on a 3 T MRI unit (Philips Achieva) using a 32-element phased-array head coil. We used an axial T~2~-weighted MRI sequence \[five slices, echo time = 100 ms, repetition time = 3000 ms, acquired voxel-size 0.57/0.76/8 mm^3^ (interpolated to 0.45/0.45/8 mm^3^), field of view = 230 × 119 mm^2^\] with same orientation and slice thickness (8 mm) as our DCE-MRI sequence, in order to manually draw regions of interest in the periventricular normal-appearing white matter, and in the normal-appearing thalamic grey matter in both hemispheres, avoiding inclusion of or proximity to any multiple sclerosis lesions, as previously described in detail ([@awv203-B7]). Examples of region of interest placement can be seen in [Figs 1--3](#awv203-F1 awv203-F2 awv203-F3){ref-type="fig"}. T~2~ lesions were defined as a T~2~ hyperintensity \>3 mm in size with a typical anatomical location for multiple sclerosis, i.e. periventricular, juxtacortical or infratentorial. In addition T~2~ lesions \>3 mm in size in subcortical and deep white matter were also included in total T~2~ lesion count. This procedure was performed by an experienced neuroradiologist using an axial T~2~ fluid attenuation inversion recovery (FLAIR) sequence \[35 slices, echo time = 125 ms, repetition time = 11 000 ms, acquired voxel-size 0.65/0.99/3.5 mm^3^ (interpolated to 0.45/0.45/3.5 mm^3^), field-of-view = 230 × 119 mm^2^, slice thickness of 3.5 mm\]. Figure 1**Healthy control subject**. (**A**) T~2~-weighted sequence on which region of interest placement is performed. Purple: normal-appearing white matter; orange: thalamus; red: lesions. (**B**) Corresponding DCE slices. (**C**) Voxel-wise permeability maps, measured as *K~i~* in ml/100 g/min. Figure 2**Patient with optic neuritis that did not convert to multiple sclerosis**. (**A**) T~2~-weighted sequence on which region of interest placement is performed. Purple: normal-appearing white matter; orange: thalamus; red: lesions. (**B**) Corresponding DCE-MRI slices. (**C**) Voxel-wise permeability maps, measured as *K~i~* in ml/100 g/min. Figure 3**Optic neuritis patient with conversion to multiple sclerosis**. (**A**) T~2~-weighted sequence on which region of interest placement is performed. Purple: normal-appearing white matter; Orange: thalamus; Red: lesions. (**B**) Corresponding DCE slices. (**C**) Voxel-wise permeability maps, measured as *K~i~* in ml/100 g/min. Note the higher permeability values in normal-appearing white matter, when compared to [Fig. 2](#awv203-F2){ref-type="fig"}, which has the same scaling. A small contrast-enhancing lesion that was visible on post-contrast T~1~ image (not shown) is marked by red arrows. Note that the model fit is more prone to noise-related errors when conducted on a voxel-wise basis compared to the region of interest-based approach used in the article. Also note that the high permeability values in some parts of the ventricular system are caused by the choroid plexus, where fenestrated capillaries and lack of tight junctions allow passage of contrast agent into the interstitial spaces.

### Dynamic contrast enhanced MRI

DCE-MRI used a T~1~-weighted saturation-recovery gradient-echo sequence with flip angle 30°, repetition time = 3.9 ms, echo time = 1.9 ms, centric phase ordering, parallel imaging factor 2, acquired matrix 96 × 61, acquired voxel-size 2.40/2.98/8 mm^3^ (interpolated to 0.90/0.89/8 mm^3^), field of view 230 × 182 mm^2^, five slices, slice thickness 8 mm. Data for an initial measurement of relaxation time (T~1~) and equilibrium magnetization (M~0~) were generated using a series of saturation time delays from 120 ms to 10 s, covering the same slices as imaged during the bolus passage. The dynamic sequence used a saturation time delay of 120 ms, giving a time resolution of 1.25 s, and 750 time points, corresponding to a total sampling duration 15.7 min. More details can be found in [@awv203-B7].

### Permeability estimation

The DCE-MRI data were analysed with a semi-automatic procedure ([@awv203-B18]) using in-house MatLab-based software. The DCE-MRI time series was converted to units of contrast agent concentration using T~1~ and M~0~ ([@awv203-B7]). The input function was corrected for partial volume by normalizing to a phase-derived venous outflow function, free of any partial volume effects ([@awv203-B31]), sampled in the sagittal sinus ([@awv203-B14]). Tissue concentration-time curves were evaluated using a combination of model free deconvolution and a two-compartment model, after which the median value was taken from each region of interest, as described in previous work ([@awv203-B17]). Permeability values are reported as *K~i~* in the unit of ml/100 g/min assuming brain tissue density of 1 g/ml \[*K~i~* = *K^trans^* /(1 − *Hct*)\].

Statistics
----------

We used Mann-Whitney U-tests and Spearman rank correlations due to small sample size and a *P*-value lower than 0.05 to allow us to reject the null hypothesis. Forward stepwise logistic regression with multiple sclerosis at 2 years as outcome was used to estimate the relative risk increase for the different risk factors. Receiver operating characteristic (ROC) curves were used to estimate the ability of a risk factor to predict conversion to multiple sclerosis and establish a cut-off value providing the best combined sensitivity and specificity.

Ethics
------

This study was approved by the Ethics Committee of Copenhagen County according to the standards of The National Committee on Health Research Ethics, protocol number H-D-2008-002 (MRI protocol) and H1-2011-019 (biomarker protocol). All experiments were conducted in accordance with the Declaration of Helsinki of 1975 and all subjects gave written informed consent.

Results
=======

Baseline characteristics of patients with optic neuritis and healthy controls are shown in [Table 1](#awv203-T1){ref-type="table"}. There were no significant differences in age and gender between patients and healthy controls. Seventeen patients of 39 (44%) were diagnosed with multiple sclerosis during the observation period of 2 years and the frequency of clinical visits and MRI scans in this group was not influenced by the study protocol. Thirteen of these 17 multiple sclerosis converters (94%) were started on first line disease-modifying treatment within 2--6 weeks after baseline visit. Four of these after a diagnosis of multiple sclerosis was made on the first scan, and the remaining as preventative treatment due to perceived high risk of future multiple sclerosis development ([Fig. 4](#awv203-F4){ref-type="fig"}). The decision of initiating first line disease-modifying treatment (Interferon beta 1a in all cases) was made by an experienced multiple sclerosis neurologist at the multiple sclerosis clinic at Glostrup Hospital and was not influenced by the study in any way. Prophylactic disease-modifying treatment was initiated in accordance with international recommendations ([@awv203-B6]) within 2--6 weeks after onset of optic neuritis. The timing of initiation of treatment and diagnosis of multiple sclerosis for the patients who converted to multiple sclerosis can be seen in [Fig. 4](#awv203-F4){ref-type="fig"}. One patient was transferred to another healthcare centre during the observation period and was excluded from analysis related to multiple sclerosis risk. The remaining 21 patients who were not diagnosed with multiple sclerosis during the 2-year period all had a minimum of one routine MRI at 6 months and clinical assessment at 12 months to make sure that none had new MRI lesions or relapses. Six of the 21 non-converters (29%) were started on disease-modifying treatment within 2--6 weeks after onset of optic neuritis. At 2 years after optic neuritis onset, clinical assessment was made either in person (*n* = 10) or by telephone interview (*n* = 11). Example permeability maps from one healthy control and two optic neuritis patients; one multiple sclerosis converter and one non-converter can be seen in [Figs 1--3](#awv203-F1 awv203-F2 awv203-F3){ref-type="fig"}. Figure 4**Cumulative incidence of conversion from optic neuritis to multiple sclerosis**. The diagram shows the timing of multiple sclerosis (MS) diagnosis and initiation of first-line disease modifying treatment (interferon beta 1a). Note that all patients were untreated at optic neuritis (ON) onset, and decision for treatment initiation was made as either a preventative measure or after multiple sclerosis diagnosis. This decision was made by multiple sclerosis specialist doctors and was not influenced by the study. Red asterisk indicates that patient started on disease-modifying treatment at the same time as multiple sclerosis diagnosis. Blue asterisk indicates that patient started on preventative disease-modifying treatment 2--6 weeks after optic neuritis onset. Table 1Clinical characteristics of optic neuritis patients and healthy controlsON patients; all (*n* = 39)ON patients; MS converters (*n* = 17)ON patients; non-converters (*n* = 21)Healthy controls (*n* = 18)*P*-value for difference[^c^](#awv203-TF3){ref-type="table-fn"}Age (years)[^a^](#awv203-TF1){ref-type="table-fn"}37 (10)37 (10)38 (13)33(10)0.16Gender (number of females)33 (77%)11 (65%)18 (86%)12 (67%)0.41Haematocrit0.43 (0.03)0.44 (0.03)0.42 (0.03)0.42 (0.03)0.14Blood--brain barrier permeability (ml/100 g/min)Periventricular NAWM[^a^](#awv203-TF1){ref-type="table-fn"}0.15 (0.07)0.18 (0.08)0.12 (0.05)0.10 (0.05)0.017ROI size (voxels)118 (53)122 (62)109 (49)135 (71)0.32Thalamic grey matter[^a^](#awv203-TF1){ref-type="table-fn"}0.12 (0.06)0.14 (0.06)0.09 (0.05)0.11 (0.06)0.74ROI size (voxels)113 (30)111 (36)117 (23)101 (41)0.22Biomarkers in CSF**(*n* = 12)**Positive IgG index16 (42%) (*n* = 38)[^e^](#awv203-TF5){ref-type="table-fn"}8 (50%)8 (38%)0--Positive OCB25 (64%) (*n* = 39)14 (82%)10 (48%)0--Leucocytes (mio/l)[^b^](#awv203-TF2){ref-type="table-fn"}9 (12) (*n* = 38)[^e^](#awv203-TF5){ref-type="table-fn"}15 (15)5 (5)3 (2)0.001CXCL10 (pg/ml)[^b^](#awv203-TF2){ref-type="table-fn"}268 (227) (*n* = 34)364 (287)199 (132)128 (85.3)0.012CXCL13 (pg/ml)[^b^](#awv203-TF2){ref-type="table-fn"}37.7 (87.9) (*n* = 34)57.0 (125)23.7 (40.0)3.9[^d^](#awv203-TF4){ref-type="table-fn"}0.0005MMP9 (ng/ml)[^b^](#awv203-TF2){ref-type="table-fn"}0.66 (1.24) (*n* = 34)1.13 (1.77)0.30 (0.24)0.156[^d^](#awv203-TF4){ref-type="table-fn"}0.001[^2][^3][^4][^5][^6][^7]

BBB permeability and risk of multiple sclerosis
-----------------------------------------------

In the whole group of optic neuritis patients we found a significantly higher BBB permeability in periventricular normal-appearing white matter compared to healthy control subjects (*P* = 0.017; Mann-Whitney U-test) ([Table 1](#awv203-T1){ref-type="table"}[Supplementary Fig. 2](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awv203/-/DC1)). In deep grey matter (thalamus) the two groups had similar permeability values. In patients who developed multiple sclerosis within 2 years from optic neuritis onset (*n* = 17), we found significantly higher permeability in normal-appearing white matter (*P =*0.004; Mann-Whitney U-test) and in the thalamus (*P =*0.003; Mann-Whitney U-test) compared to patients who did not develop multiple sclerosis (*n* = 21). To investigate how well BBB permeability at optic neuritis onset predicted conversion to multiple sclerosis after 2 years, we performed a forward stepwise multivariate logistic regression analysis ([Table 2](#awv203-T2){ref-type="table"}). Having \>9 T~2~ lesions on baseline MRI increased the risk of multiple sclerosis 52.6 times (*P =*0.002) as previously shown ([@awv203-B2]; [@awv203-B29]). An increase in permeability in normal-appearing white matter of 0.1 ml/100 g/min increased the risk 8.5 times (*P =*0.03). Model Nagelkerke R^2^= 0.60, *P =*0.007. Number of T~2~ lesions alone provided a Nagelkerke R^2^= 0.47, but adding permeability in normal-appearing white matter significantly improved prediction of multiple sclerosis development (*P =*0.007). To calculate the best cut-off value for permeability in normal-appearing white matter for multiple sclerosis prediction we conducted a ROC analysis, yielding an area under the curve of 0.77 \[95% confidence interval (CI) 0.60--0.93\], *P =*0.005 ([Table 3](#awv203-T3){ref-type="table"}). A threshold of permeability in normal-appearing white matter \>0.13 ml/100 g/min predicted conversion to multiple sclerosis with a sensitivity of 88% and a specificity of 72%. For comparison ROC curve specifications for other predictors of multiple sclerosis development can also be seen in [Table 3](#awv203-T3){ref-type="table"}. Comparing permeability in normal-appearing white matter to T~2~ lesion count we found no significant difference between ROC curve areas under the curve (*P =*0.42 and *P =*0.44, respectively). CSF leucocytosis has previously been shown to predict conversion from clinically isolated syndrome to clinically definite multiple sclerosis ([@awv203-B13]; [@awv203-B22]), but leucocyte count just fell outside significance in the logistic regression model. Permeability in normal-appearing white matter and in the thalamus were significantly correlated in the optic neuritis patients \[correlation coefficient (CC) 0.62, *P =*0.00002\]. Entering permeability in thalamus (instead of normal-appearing white matter to avoid colinearity) to the logistic regression analysis showed that permeability in the thalamus together with T~2~ lesion count was also a significant predictor of multiple sclerosis development (OR 8.3; *P =*0.035). We found no correlation between permeability in normal-appearing white matter and the T~2~ lesion count (Spearman CC = 0.13, *P =*0.44) ([Supplementary Fig. 3](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awv203/-/DC1)) or T~2~ lesions load (CC = 0.25, *P =*0.19) indicating that permeability and T~2~ lesions may provide different pathophysiological information. Table 2Results of stepwise multivariate logistic regression with multiple sclerosis at 2 years as dependent variableVariableValuesPatients, *n*MS conversion rate (%)*P*-valueOdds ratio95% CINumber of white matter lesions0--112170.006[**^a^**](#awv203-TF12){ref-type="table-fn"}--2--813310.423.7[**^b^**](#awv203-TF13){ref-type="table-fn"}0.43--32.3≥ 913790.00252.6[**^b^**](#awv203-TF13){ref-type="table-fn"}3.3--233Permeability in NAWM------0.038.5[**^c^**](#awv203-TF14){ref-type="table-fn"}1.97--40.8Oligoclonal bandsYes22550.06----No1225CSF leucocyte count------0.08----Age------0.18----GenderFemale29380.46----Male967CELYes41000.99[**^d^**](#awv203-TF15){ref-type="table-fn"}----No3438[^8][^9][^10][^11][^12][^13] Table 3Results of receiver operating characteristic curve analysisROC analysisAUC*P*-valueOptimal cut-offSensitivitySpecificityT~2~ lesion count0.86 (CI 0.73--0.98)0.0001\>577%82%Permeability in NAWM0.77 (CI 0.60--0.93)0.0050.13 ml/100 g/min88%71%Permeability in the thalamus0.78 (CI 0.63--0.93)0.0030.09 ml/100 g/min82%62%CSF leucocytes0.77 (CI 0.62--0.92)0.005\>5 mio/l71%71%Oligoclonal bands0.670.069--82%48%[^14]

Correlations between BBB permeability and CSF biomarkers
--------------------------------------------------------

The results of the correlation analysis can be seen in [Table 4](#awv203-T4){ref-type="table"}. For patients with optic neuritis we found a significant correlation between BBB permeability and CSF leucocyte count; Spearman correlation coefficient (CC) = 0.57; *P =*0.0002 ([Fig. 5](#awv203-F5){ref-type="fig"}). For CLCX10 we found a CC of 0.40 (*P =*0.02) with BBB permeability. The MMP9 values of 13 patients were below the detection limit of the assay, for which reason we used a censored regression analysis (Tobit) to avoid improper weighting of the large number of non-detectable values. This analysis showed a significant linear trend (*P =*0.034). We found no significant correlations between permeability in normal-appearing white matter and CLCX13 (*P =*0.24), neither did we find any correlations between permeability in the thalamus and CSF leucocytes (*P =*0.06), CLCX10 (*P =*0.31), MMP9 (*P =*0.06) or CLCX13 (*P =*0.06). There were significant intercorrelations between the following CSF biomarkers: CSF leucocyte count, IgG index, oligoclonal bands, CLCX10, CLCX13 and MMP9, as previously shown by us and others ([@awv203-B27]; [@awv203-B16]; [@awv203-B21]). Figure 5**Permeability of the BBB in periventricular normal-appearing white matter plotted against CSF leucocyte count in optic neuritis patients**. The blue circle and green star icons indicates multiple sclerosis conversion status for each patient after 2 years. Spearman CC 0.57; *P =*0.0002. Linear fit line added for visualization purposes only. No data = no information on multiple sclerosis conversion status. NAWM = normal-appearing white matter. Table 4Relationship between permeability in normal-appearing white matter and investigated variables in patients with optic neuritisCSF biomarkersCC*P*-value*n*IgG index0.170.3538[^a^](#awv203-TF7){ref-type="table-fn"}Oligoclonal bandsn/a0.72[^c^](#awv203-TF9){ref-type="table-fn"}39Leucocyte count (mio/l)0.570.000238[^a^](#awv203-TF7){ref-type="table-fn"}CXCL10 (pg/ml)0.400.0234MMP9 (ng/ml)n/a0.034[^b^](#awv203-TF8){ref-type="table-fn"}34CXCL13 (pg/ml)0.110.5534Albumin index (CSF/serum)−0.020.9138[^a^](#awv203-TF7){ref-type="table-fn"}MRI variables    T~2~ lesion count0.130.4439    T~2~ lesion load (mm^3^)0.250.1939[^15][^16][^17]

Discussion
==========

In this study of a prospective cohort of optic neuritis patients we found that BBB permeability measured by DCE-MRI in periventricular normal-appearing white matter and the thalamus provides prognostic information about multiple sclerosis conversion after 2 years. MRI measured permeability seems to provide supplementary information compared to existing MRI risk parameters, as it is neither correlated to T~2~ lesion count nor T~2~ lesion load. This indicates that the BBB permeability changes observed in this study are not simply the result of secondary myelin degradation and BBB damage due to Wallerian or retrograde degeneration. Moreover, we found that BBB permeability is correlated with CSF leucocyte count, CLCX10 and MMP9 concentrations in CSF. CXCL10 is a chemokine that attracts activated T cells through its receptor, CXCR3, and it is present at higher concentrations in the CSF of multiple sclerosis patients with active demyelinating attacks when compared to neurological controls ([@awv203-B28]). MMP9 is secreted by lymphocytes and macrophages, facilitating their migration across glia limitans basement membranes ([@awv203-B19]; [@awv203-B1]), and MMP9 has been suggested as a surrogate marker of disease activity in multiple sclerosis ([@awv203-B27]). The association between these CSF biomarkers and MRI quantification of BBB permeability seems to suggest that although the method is Gd-DTPA based, it may to some extent reflect the cellular permeability of the BBB. We have previously reported that patients with relapsing-remitting multiple sclerosis experiencing a relapse had higher permeability values in normal-appearing white matter and that immunomodulatory treatment attenuated this increase ([@awv203-B7]). Interestingly, the absolute level of permeability in untreated patients with relapsing-remitting multiple sclerosis was very similar to that of the optic neuritis patients who converted to multiple sclerosis in this study (*K~i~* of 0.18 and 0.12 ml/100 g/min, respectively), arguing that widespread BBB opening in lesions as well as normal-appearing brain tissue might be linked directly to central pathophysiological mechanisms in multiple sclerosis. Taken together, these results indicate that permeability may provide a snapshot of the current level of multiple sclerosis-related neuroinflammation, whereas T~2~ lesions may reflect the length of the subclinical pre-relapse phase.

We observe a conversion rate from optic neuritis to multiple sclerosis based on the 2010 McDonald criteria of 45% and to clinically definite multiple sclerosis of 16% at 2 years, which is slightly lower than reported elsewhere. [@awv203-B11]reported conversion rates to McDonald multiple sclerosis after clinically isolated syndrome of 57% at 2 years; which is in line with previous reports of lower risk of conversion to multiple sclerosis after optic neuritis when compared to clinically isolated syndrome in general ([@awv203-B32]). D\'Alessandro *et al.* included a broad spectrum of patients with clinically isolated syndrome retrospectively with symptoms suggestive of multiple sclerosis from the past 6 months. Also, a slightly higher proportion of patients in our study were started on disease-modifying drugs 2--6 weeks after onset of optic neuritis (58%), compared to 49% in the study by [@awv203-B11]who were started within the first year.

Six patients converted to multiple sclerosis shortly after baseline MRI, four due to positivity of the dissemination in time criteria ([Fig. 4](#awv203-F4){ref-type="fig"}). In an attempt to evaluate if permeability would be of any use in a clinical setting, we excluded these six patients from the data set and found that permeability in normal-appearing white matter (*P =*0.027) and CSF leucocyte count (*P =*0.023) were now significant predictors of multiple sclerosis conversion with Nagelkerke R^2^= 0.64 and *P* = 0.001. Permeability in thalamus was also significant (*P =*0.019) when added instead of normal-appearing white matter permeability. T~2~ lesion count was no longer significant, presumably due to exclusion of six subjects with high lesion count driving the significance. ROC curve analysis for permeability in normal-appearing white matter now showed an area under the curve of 0.81, *P =*0.005 and a threshold of 0.13 ml/100 g/min gave a sensitivity of 91% and specificity of 71%. ROC curve analysis of CSF leucocyte count gave an area under the curve of 0.85; *P =*0.001, and a threshold of 5 mio/l leucocytes gave a sensitivity of 82% and sensitivity of 71%. Four multiple sclerosis converters were not started on preventative disease-modifying treatment due to a low perceived multiple sclerosis risk (\<3 white matter lesions; negative dissemination in space criteria; three had positive oligoclonal bands; three had CSF leucocytes\>5mio/l). All four had permeability in normal-appearing white matter \>0.13ml/100 g/min ([Fig. 6](#awv203-F6){ref-type="fig"}). Thus, clinical access to a complementary biomarker of neuroinflammation might provide extra risk information in a subset of patients. Future prospects after optic neuritis are still very diverse, which merits further studying of potential biomarkers of multiple sclerosis conversion such as MRI permeability. Figure 6**Performance of T~2~ lesion count, permeability in normal-appearing white matter and CSF leucocytes to predict multiple sclerosis conversion**. The vertical dotted line represents the normal-appearing white matter permeability threshold level of 0.13 ml/100 g/min found in the ROC analysis. Four patients (circled with green) were not started on disease-modifying treatment in part due to a low perceived future multiple sclerosis risk. However, all four had normal-appearing white matter permeability \>0.13 ml/100 g/min and three had CSF leucocytes \>5 mio/l. The blue circle highlights the six false positives that did not develop multiple sclerosis but had permeability \>0.13 ml/100 g/min. NAWM = normal-appearing white matter.

Permeability in normal-appearing white matter and in the thalamus
-----------------------------------------------------------------

We found that permeability in both normal-appearing white matter and in the thalamus provide novel information on multiple sclerosis conversion, when compared to using T~2~ lesions alone. This finding fits well with previous multiple sclerosis studies indicating early pathological changes in the thalamus such as atrophy, altered mean diffusivity, reduced *N*-acetyl-aspartate concentration and iron accumulation, whereas T~2~ lesions are more pronounced in the later stages of the multiple sclerosis disease ([@awv203-B20]). However, we did not find a significant correlation between permeability in the thalamus and CSF biomarkers of leucocyte trafficking nor was thalamic permeability higher in the whole group of optic neuritis patients when compared to healthy controls. Although multiple sclerosis is increasingly being acknowledged as also being a grey matter disease, research has found that grey matter involvement differs significantly from white matter lesions. Features such as lymphocyte infiltration, complement deposition and BBB disruption are typically not detected in grey matter of autopsy samples and diffuse microglial activation is detectable in thalamic normal-appearing grey matter, but to a lesser extent than in the normal-appearing white matter ([@awv203-B30]; [@awv203-B25]). As the thalamus is comprised of a mixture of clusters of grey matter nuclei separated by medullary laminae of myelinated fibres, as well as larger tracts of white matter bundles, it seems plausible to assume that permeability as measured by DCE-MRI may primarily reflect the neuroinflammatory processes, which appears to be most prominent in the myelinated areas of the brain.

Limitations in study design
---------------------------

An important limitation in this study is the non-uniformity of which the follow-up procedure was performed. Optic neuritis patients who had many baseline white matter lesions were---for clinical reasons---investigated more intensively with MRI and clinical evaluation than those who had few white matter lesions, introducing a possible bias towards earlier diagnosis. On the other hand, those with many white matter lesions were frequently initiated in immunomodulatory treatment, presumably delaying conversion to multiple sclerosis. This bias may explain the heterogeneity in permeability values in the subset of optic neuritis patients who did not convert to multiple sclerosis. However, immunomodulatory treatment after the first relapse is now becoming the norm in patients with high multiple sclerosis risk, and any biomarker faces the challenge of having to perform within the frame of the actual everyday clinical set-up.

Methodological considerations
-----------------------------

As the DCE-MRI method that we apply in this study attempts to measure very subtle differences in BBB permeability, we have previously published work testing the accuracy and precision of the method. We found that the method was able to significantly distinguish values as low as 0.1 ml/100 g/min from zero, provided that we use a long total measurement time of 15 min and a high time resolution of ∼1 s ([@awv203-B7]). The conclusions of this study are thus based on a strong theoretical and methodological foundation. In this study, we chose to define regions of interest manually after careful consideration of the advantages and disadvantages compared to a more automated segmentation-based approach. Manual region of interest placement allows us to ensure similar size between all subjects and gives us better control of potential partial volume errors from CSF, vessels, grey matter and multiple sclerosis lesions. Every time a region of interest was placed, we looked through the corresponding three slices of a FLAIR T~2~ with a slice thickness of 3.5 mm and same angulation as the 8 mm DCE slices. However, region of interest placement will still inevitably be different between subjects with high and low lesion loads. In an attempt to quantify this effect we conducted a test--retest reliability analysis that consisted of replacing the normal-appearing white matter regions of interest twice in the 15 subjects with two or fewer T~2~ lesions, to a location more typical of a subject with high lesion load ([Supplementary Fig. 4](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awv203/-/DC1)). Test--retest analysis gave a Crohnbach alpha of 0.94 and using the new values, did not change any of the results of the study. In addition, the lack of correlation between permeability on one side and lesion count and lesion load on the other, together with the fact that permeability in the thalamus also significantly predicted multiple sclerosis development, argues that our findings are not a result of region of interest positioning differences between subgroups with high and low lesion load.

BBB breach in optic neuritis and multiple sclerosis
---------------------------------------------------

The classic view of the CNS as a site of complete immunoprivilege has been challenged by the observation that activated T cells are readily able to penetrate the endothelial cell layer at the level of the post-capillary venules. Here they perform immune-surveillance in the perivascular and subarachnoid spaces without disturbing the barrier capabilities of the BBB ([@awv203-B4]). Solute diffusion across the BBB is---on the other hand---controlled at the capillary level, hence it is important to acknowledge that permeability of solutes and cells are not the same ([@awv203-B3]). When activated T cells in the perivascular spaces encounter their specific antigen presenting cell they signal for opening of the endothelial cell layer through chemokines and interleukins, hereby mounting an immune response that attracts further immune cells to the site. The inner barrier, which is comprised of the glia limitans and its basement membrane, is then breached and an immune response mounted into the neuropil itself ([@awv203-B4]). Keeping this in mind, it remains challenging to conceive whether the subtle permeability increases we observe in normal-appearing white matter reflect trapping of contrast agent in the perivascular spaces or accumulation into the neuropil itself. The mechanisms for Gd-DTPA passage across the BBB is not known in detail, but increased passage of a large variety of macromolecules has been observed in the context of inflammation and enhanced cellular permeability in animal models of multiple sclerosis, and is generally considered to be the result of secondary opening of tight junctions, enhanced pinocytotic activity, or formation of transendothelial channels ([@awv203-B15]; [@awv203-B5]; [@awv203-B10]). T cell-derived cytokines may influence transport of various compounds into the brain and *in vitro* studies have shown that administration of TNF, IL1, and IL6 to monolayers of endothelial cells leads to an increase in the solute permeability ([@awv203-B9]). Thus, a very plausible mechanism for increased passage of Gd-DTPA across the BBB in the presence of inflammation, is that when activated T cells in the perivascular spaces encounter their specific antigen they elicit secondary widespread permeability changes of the BBB endothelial cell layer at both the post-capillary and capillary level resulting in increased 'bystander' passage of Gd-DTPA into the perivascular spaces. However, we also found a correlation between Gd-DTPA permeability and MMP9, which is required for degradation of laminin 1 and 2 of the glia limitans ([@awv203-B3]; [@awv203-B4]). This indicates that Gd-DTPA-based measurements of BBB at least to some extent may reflect the cellular permeability into the neuropil itself. We found no correlation between permeability and CSF levels of albumin, measured as the albumin CSF/serum index, but all patients and healthy control subjects had values within normal range. This indicates that Gd-DTPA (547 Da), with a molecular weight more than 100 times smaller than albumin (66 437 Da), may be a more sensitive marker of low-grade BBB permeability changes.

Perspectives
============

In this study we found that permeability of the BBB in normal-appearing white matter, as measured by MRI, may provide novel pathological information on neuroinflammation in optic neuritis and multiple sclerosis, possibly providing a 'snapshot' of the present level of multiple sclerosis-related CNS inflammation. Currently, the most widely used measures of multiple sclerosis disease activity are occurrence of new MRI lesions and/or clinical relapses, but these measures do not always correlate well with long-term disability outcomes in clinical multiple sclerosis trials ([@awv203-B26]) or annual atrophy rates in so-called benign multiple sclerosis ([@awv203-B12]). This indicates the existence of ongoing subclinical disease activity even in the absence of relapses or MRI activity. Hence, a new marker of low-grade multiple sclerosis disease activity could have many useful applications, i.e. subclinical disease activity monitoring or identification of inadequate treatment response before the next relapse occurs. Furthermore, quantification of BBB permeability may constitute an early prognostic factor in the pathogenesis of multiple sclerosis, while MRI features such as multiple sclerosis plaques, loss of *N*-acetyl-aspartate, decrease of magnetic transfer ratio (MTR), changes in T~1~, and tissue atrophy may be considered as consequences of a longer lasting neuroinflammation.
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BBB

:   blood--brain barrier

DCE-MRI

:   dynamic contrast-enhanced MRI

IgG

:   immunoglobulin G

[^1]: See Naismith and Cross (doi:10.1093/brain/awv196) for a scientific commentary on this article.

[^2]: ^a^Mean and standard deviation.

[^3]: ^b^Median and interquartile range.

[^4]: ^c^Between all optic neuritis patients and healthy controls. Mann-Whitney U or chi square tests where appropriate.

[^5]: ^d^All healthy controls had below threshold values.

[^6]: ^e^Due to high erythrocyte count in CSF we excluded IgG index and leucocyte count one patient.

[^7]: MS = multiple sclerosis; NAWM = normal-appearing white matter; ON = optic neuritis; OCB = oligoclonal bands; ROI = region of interest.

[^8]: Number of white matter lesions and permeability in normal-appearing white matter provided the best model with a Nagelkerke R^2^= 0.66; *P =*0.00004. Adding number of white matter lesions alone to the model provided a Nagelkerke R^2^= 0.42, but adding permeability in normal-appearing white matter significantly improved the model accuracy (R^2^= 0.56; *P* = 0.007), and adding oligoclonal bands provided (R^2^= 0.66; *P* = 0.02). Permeability in the thalamus was also a significant predictor of multiple sclerosis (*P* = 0.035), when entered instead of normal-appearing white matter permeability, but was left out to avoid problems of colinearity.

[^9]: CEL = contrast enhancing lesions; NAWM = normal-appearing white matter; MS = multiple sclerosis.

[^10]: ^a^*P*-value for the categorical variable.

[^11]: ^b^Odds ratio when compared to the first group having 0--1 white matter lesions.

[^12]: ^c^Odds ratio for an increase in permeability of 0.1 ml/100 g/min.

[^13]: ^d^All contrast enhancing lesion positive patients had more than six lesions and permeability in normal-appearing white matter \>0.13, thus contrast enhancing lesions did not provide additional risk information in this study.

[^14]: AUC = area under the curve; NAWM = normal-appearing white matter; ROC = receiver operating characteristic.

[^15]: ^a^Due to high erythrocyte count in CSF we excluded IgG index, leucocyte count and albumin index for one patient.

[^16]: ^b^Censored regression (Tobit) analysis.

[^17]: ^c^Logistic regression analysis. CC = correlation coefficient.
